India Pharma and Healthcare Sector Report 2024-2025

India's pharmaceutical and healthcare sector is world-renowned. India is known as the "pharmacy of the world" due to its prolific output of generic medicines and vaccines; in particular, the Indian vaccine producer, Serum Institute of India, played a crucial role in producing vaccines to combat the COVID-19 pandemic. Meanwhile, thanks to their reputation for providing excellent yet affordable healthcare, India's hospitals are catering to an increasing number of medical tourists. Patients in India are increasingly able to access modern healthcare, owing primarily to increased participation in Ayushman Bharat, the government-funded public health insurance programme. Despite these encouraging signs, India's pharmaceutical and healthcare sectors face several pressing challenges. Due to decades of underfunding and a constant exodus of skilled medical professionals to higher-paying countries, India has limited healthcare infrastructure. Because of limitations in domestic production capacity, the Indian healthcare system also relies on imported medical devices, pharmaceutical raw materials, and patented drugs.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors